Johnson Matthey (JMAT) – Investment Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Johnson Matthey (LON: JMAT) recently:

• 6/1/2026 – Johnson Matthey had its price target raised by Berenberg Bank from GBX 2,100 to GBX 2,300. They now have a “buy” rating on the stock.
• 5/29/2026 – Johnson Matthey had its price target raised by Deutsche Bank Aktiengesellschaft from GBX 2,120 to GBX 2,400. They now have a “buy” rating on the stock.
• 5/29/2026 – Johnson Matthey had its “restricted” rating reaffirmed by Jefferies Financial Group Inc..
• 5/22/2026 – Johnson Matthey had its “neutral” rating reaffirmed by UBS Group AG. They now have a GBX 2,200 price target on the stock.

Insider Transactions at Johnson Matthey

In related news, insider Alastair Judge bought 14 shares of the business’s stock in a transaction dated Wednesday, April 15th. The shares were bought at an average cost of GBX 2,022 per share, with a total value of £283.08. Also, insider Liam Condon bought 4,500 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were bought at an average cost of GBX 2,127 per share, for a total transaction of £95,715. Insiders have purchased 11,430 shares of company stock valued at $24,591,744 over the last three months. Company insiders own 0.51% of the company’s stock.

Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources. Today more than 13,000 Johnson Matthey professionals collaborate with their network of customers and partners to make a real difference to the world around us.